Edmonds 1994.

Study characteristics
Methods	Trial design: Randomised controlled trial
Participants	Participants: 50 women were randomised and analysed. Mean age: not stated Inclusion criteria: Laparoscopic confirmed endometriosis Significant pelvic pain Exclusion criteria:  No pelvic pain Setting: United Kingdom Timing: not stated
Interventions	Group 1: goserelin 3.6 mg/month as SC depot (n = 25) versus Group 2: goserelin 3.6 mg/month as SC depot + 17‐oestrodiol 25 ug through the skin twice weekly and medroxyprogesterone acetate 5 mg/day PO (n = 25)
Outcomes	Bone mineral density, measured at the lumbar spine, femoral neck and ward's triangle Improvement of most troublesome symptom: dyspareunia, dysmenorrhoea, pelvic pain, pelvic tenderness, induration combined Endocrine profiles
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: not stated   Author could not be contacted for further information because of lack of contact information.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'Randomised controlled trial'. No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details provided of blinding of participants or personnel
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided of blinding of outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses to follow‐up
Selective reporting (reporting bias)	High risk	Change in pain‐related symptoms was asked for, but not reported in published article.
Other bias	Low risk	No other risk of bias detected